ea0041ep736 | Neuroendocrinology | ECE2016
Pivonello Rosario
, Arnaldi Giorgio
, Scaroni Carla Maria
, Giordano Carla
, Cannavo Salvatore
, Iacuaniello Davide
, Trementino Laura
, Zilio Marialuisa
, Guarnotta Valentina
, Albani Adriana
, Cozzolino Alessia
, Michetti Grazia
, Boscaro Marco
, Colao Annamaria
A recent phase III clinical trial has demonstrated that the treatment with the somatostatin analogue pasireotide normalizes cortisol secretion in 1528% of patients with Cushings disease (CD). The aim of the current study was to evaluate the effectiveness of 6-months pasireotide treatment on clinical and hormonal profiles in a group of CD patients with mild to moderate disease according with the real-word evidence. Thirty-two patients with CD unsuccessfully treated ...